Cytomedix Announces Multiple Poster Presentations at the 44th Annual Conference of the Wound Ostomy Continence Nurses …

Posted: Published on June 9th, 2012

This post was added by Dr. Richardson

GAITHERSBURG, MD--(Marketwire -06/08/12)- Cytomedix, Inc. (CMXI) (the "Company"), a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies for wound and tissue repair, today announced that four poster presentations highlighting the clinical merits of the Company's AutoloGel System in wound management will be presented at the 44th Annual Conference of the Wound Ostomy and Continence Nurses Society ("WOCN") being held in Charlotte, North Carolina from June 9-13, 2012.

The AutoloGel System, a device for the production of autologous platelet rich plasma ("PRP") gel, is the only PRP device cleared by the U.S. Food and Drug Administration ("FDA") for use in wound management.

The following posters highlighting Cytomedix's PRP technology will be presented at WOCN 2012:

"This body of clinical data demonstrates AutoloGel's ability to accelerate wound healing in common wound etiologies and also shows its effectiveness on fistulas, pseudostomas, and pressure ulcers in persons with spinal cord injury, which are all notoriously difficult to heal wounds. In addition, the data shows that AutoloGel saves money while increasing healing rates and decreasing staff time," commented Carelyn P. Fylling, RN, MSN, CWS, CLNC, Cytomedix's Vice President of Professional Services.

"We are pleased to have these four posters presented at WOCN as it offers an ideal venue to reach and educate a large audience of clinicians who specialize in wound management on the clinical merits of AutoloGel to heal these challenging wounds. These data, collectively and individually, demonstrate the clinical utility of AutoloGel to heal a variety of hard-to-heal wounds," commented Martin P. Rosendale, Chief Executive Officer of Cytomedix. "Compelling clinical results such as these should favorably impact the adoption of AutoloGel in a variety of wounds and wound care settings, and further strengthen final negotiations with our potential top 20 global pharmaceutical partner."

The posters will be available at WOCN as follows:

Sunday, June 10 6:30 am - 8:00 pm Poster Viewing

Monday, June 11 9:00 am - 5:30 pm Poster Viewing

Tuesday, June 12 7:00 am - 9:00 am Authors Session and Awards Presentation 9:00 am - 6:30 pm Poster Viewing

Wednesday, June 13 8:00 am - 12:00 pm Poster Viewing

Continue reading here:
Cytomedix Announces Multiple Poster Presentations at the 44th Annual Conference of the Wound Ostomy Continence Nurses ...

Related Posts
This entry was posted in FDA Stem Cell Trials. Bookmark the permalink.

Comments are closed.